{"disease":{"id":"hepatitis-c","name":"Hepatitis C","therapeutic_area":"Infectious Disease","data":{"aiSummary":"The treatment landscape for Hepatitis C has been revolutionized by direct-acting antivirals (DAAs), which offer high cure rates. Current standard of care involves DAA combinations tailored to the HCV genotype. Recent advances include shorter treatment durations and pan-genotypic regimens. The pipeline focuses on developing new DAA combinations and addressing unmet needs in specific patient populations.","drug_count":5,"description":"Hepatitis C is a liver infection caused by the hepatitis C virus (HCV). It can lead to both acute and chronic liver disease, ranging from mild illness to cirrhosis and liver cancer. The virus is primarily transmitted through blood-to-blood contact, and effective treatments are available to cure the infection.","subtype_count":8},"enrichment_level":2,"last_enriched_at":null,"visit_count":0,"created_at":"2026-03-25T12:16:34.933Z","updated_at":"2026-03-25T12:16:34.933Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":0,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"eltrombopag","indication_name":"Thrombocytopenia in Chronic Hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Promacta","generic_name":"ELTROMBOPAG","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Thrombopoietin receptor","drug_class":"Thrombopoietin Receptor Agonist","quality_score":80,"revenue":"569","mechanism":"Promacta works by binding to the thrombopoietin receptor, stimulating platelet production in the bone marrow."},{"drug_id":"sovaldi","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Sovaldi","company_name":"Genuine Research Center, Egypt","drug_phase":"marketed","molecular_target":"Cereblon isoform 4, Genome polyprotein, NS5","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"interferon-alfa-2b","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Intron A","generic_name":"INTERFERON ALFA-2B","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"","drug_class":"Interferon alpha","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"beclabuvir","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"BECLABUVIR","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"boceprevir","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Victrelis","generic_name":"BOCEPREVIR","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Chymase","drug_class":"Hepatitis C Virus NS3/4A Protease Inhibitor","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"grazoprevir","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zepatier","generic_name":"GRAZOPREVIR","company_name":"Merck & Co.","drug_phase":"discontinued","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":"Zepatier blocks the NS3/4A protease enzyme, preventing the hepatitis C virus from replicating."},{"drug_id":"daklinza","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Daklinza","company_name":"Genuine Research Center, Egypt","drug_phase":"phase_1","molecular_target":"Potassium voltage-gated channel subfamily H member 2, Genome polyprotein, Nonstructural protein 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Hepatitis B (recurrence)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Hepatitis B (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Hepatitis B (pregnancy)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Hepatitis B (adolescent)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Hepatitis A (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Hepatitis A (pregnancy)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Hepatitis A (adolescent)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"peginterferon","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Peginterferon","company_name":"Ziv Hospital","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor","drug_class":"Interferon beta [EPC]","quality_score":17,"revenue":null,"mechanism":null},{"drug_id":"pediarix","indication_name":"Protection against diphtheria, tetanus, pertussis (whole-cell), hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b (Hib) disease in infants and children from 6 weeks through 6 years of age.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pediarix","generic_name":"pediarix","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Immune system","drug_class":"vaccine","quality_score":37,"revenue":null,"mechanism":""},{"drug_id":"pediarix","indication_name":"Protection against diphtheria, tetanus, pertussis (whole-cell), hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b (Hib) disease in infants and children from 6 weeks through 6 years of age, when used in a 3-dose series.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pediarix","generic_name":"pediarix","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Immune system","drug_class":"vaccine","quality_score":37,"revenue":null,"mechanism":""},{"drug_id":"pegasys","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pegasys","company_name":"Zealand University Hospital","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"ritonavir","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norvir","generic_name":"ritonavir","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C9","drug_class":"Cytochrome P450 3A Inhibitor [EPC]","quality_score":80,"revenue":null,"mechanism":"Norvir works by blocking the cytochrome P450 3A enzyme, which helps increase the levels of other medications in the body."},{"drug_id":"elbasvir","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zepatier","generic_name":"ELBASVIR","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"","drug_class":"Hepatitis C Virus NS5A Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Zepatier works by blocking the NS5A protein of the hepatitis C virus, preventing it from replicating."},{"drug_id":"daclatasvir","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Daklinza","generic_name":"DACLATASVIR","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"Hepatitis C Virus NS5A Inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"glecaprevir","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mavyret","generic_name":"GLECAPREVIR","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"","drug_class":"Hepatitis C Virus NS5A Inhibitor [EPC]","quality_score":70,"revenue":null,"mechanism":"Mavyret works by blocking the NS3/4A protease enzyme, preventing the hepatitis C virus from replicating."},{"drug_id":"asunaprevir","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sunvepra","generic_name":"ASUNAPREVIR","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"dasabuvir","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Viekira Pak (Copackaged)","generic_name":"DASABUVIR","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Protein cereblon","drug_class":"Hepatitis C Virus Non-Nucleoside NS5B Palm Polymerase Inhibitor","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"norvir","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Norvir","company_name":"Saint Michael's Medical Center","drug_phase":"marketed","molecular_target":"UDP-glucuronosyltransferase 1-1, Cytochrome P450 2C9, Multidrug and toxin extrusion protein 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ribavarin","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ribavarin","company_name":"Charles University, Czech Republic","drug_phase":"discontinued","molecular_target":"Cytosolic purine 5'-nucleotidase, Adenosine kinase, Ectonucleotide pyrophosphatase/phosphodiesterase family member 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"peginterferon-alfa-2a","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pegasys","generic_name":"PEGINTERFERON ALFA-2A","company_name":"Hoffman-La Roche","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[{"drug_id":"odalasvir-75-mg","indication_name":"Chronic hepatitis C (genotype 1)","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Odalasvir 75 mg","company_name":"Janssen Research & Development, LLC","drug_phase":"discontinued","molecular_target":"Hepatitis C virus NS5A protein","drug_class":"Direct-acting antiviral (DAA); NS5A inhibitor","quality_score":null,"revenue":null,"mechanism":"Odalasvir inhibits hepatitis C virus NS5A protein to block viral replication and assembly."},{"drug_id":"odalasvir-75-mg","indication_name":"Chronic hepatitis C (treatment-naïve and treatment-experienced)","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Odalasvir 75 mg","company_name":"Janssen Research & Development, LLC","drug_phase":"discontinued","molecular_target":"Hepatitis C virus NS5A protein","drug_class":"Direct-acting antiviral (DAA); NS5A inhibitor","quality_score":null,"revenue":null,"mechanism":"Odalasvir inhibits hepatitis C virus NS5A protein to block viral replication and assembly."},{"drug_id":"odalasvir-75-mg","indication_name":"Chronic hepatitis C (Japanese population)","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Odalasvir 75 mg","company_name":"Janssen Research & Development, LLC","drug_phase":"discontinued","molecular_target":"Hepatitis C virus NS5A protein","drug_class":"Direct-acting antiviral (DAA); NS5A inhibitor","quality_score":null,"revenue":null,"mechanism":"Odalasvir inhibits hepatitis C virus NS5A protein to block viral replication and assembly."},{"drug_id":"odv-25-mg","indication_name":"Chronic Hepatitis C (genotypes 1–6)","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ODV 25 mg","company_name":"Janssen Research & Development, LLC","drug_phase":"discontinued","molecular_target":"Hepatitis C virus NS5A protein","drug_class":"Direct-acting antiviral (DAA); NS5A inhibitor","quality_score":null,"revenue":null,"mechanism":"Odalasvir inhibits hepatitis C virus NS5A protein to block viral replication and assembly."},{"drug_id":"odalasvir-25-mg","indication_name":"Chronic hepatitis C virus infection (genotypes 1–6)","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Odalasvir 25 mg","company_name":"Janssen Research & Development, LLC","drug_phase":"discontinued","molecular_target":"Hepatitis C virus NS5A protein","drug_class":"Direct-acting antiviral (DAA); NS5A inhibitor","quality_score":null,"revenue":null,"mechanism":"Odalasvir inhibits hepatitis C virus NS5A protein to block viral replication and assembly."}],"offLabel":[],"totalMarketed":27,"totalPipeline":5},"trials":{"data":[{"nct_id":"NCT00342641","title":"Association Between Hepatitis C Virus Infection and Hematologic and Thyroid Cancers","phase":"","overall_status":"COMPLETED","enrollment_count":815000,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03944447","title":"Outcomes Mandate National Integration With Cannabis as Medicine","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":200000,"lead_sponsor_name":"OMNI Medical Services, LLC","has_results":false},{"nct_id":"NCT03200379","title":"Nation-wide Hepatitis C Virus (HCV) Registry in Taiwan","phase":"","overall_status":"RECRUITING","enrollment_count":150000,"lead_sponsor_name":"Kaohsiung Medical University Chung-Ho Memorial Hospital","has_results":false},{"nct_id":"NCT04003454","title":"The DETECT HCV Screening Trial","phase":"NA","overall_status":"COMPLETED","enrollment_count":147533,"lead_sponsor_name":"Denver Health and Hospital Authority","has_results":false},{"nct_id":"NCT05710120","title":"Hepatitis C Screening Alerts","phase":"","overall_status":"COMPLETED","enrollment_count":125706,"lead_sponsor_name":"Epividian","has_results":false},{"nct_id":"NCT05071261","title":"Screening, Treatment, and Eradication of Hep C","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":112136,"lead_sponsor_name":"Liver Institute PLLC","has_results":false},{"nct_id":"NCT06596213","title":"Hepatitis Inequalities Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":100000,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT03839979","title":"HCV Viral Hepatitis, Blood Sugar Level and Systolic Blood Pressure in Egypt","phase":"","overall_status":"COMPLETED","enrollment_count":71975,"lead_sponsor_name":"Cairo University","has_results":false},{"nct_id":"NCT05042544","title":"The Australian HCV Point-of-Care Testing Program","phase":"","overall_status":"RECRUITING","enrollment_count":60000,"lead_sponsor_name":"Kirby Institute","has_results":false},{"nct_id":"NCT05102838","title":"Prospective Cohort Study on Prognosis of Patients With Hepatitis B/C","phase":"","overall_status":"UNKNOWN","enrollment_count":60000,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT05172453","title":"Mother-to-child Transmission of HBV in China","phase":"","overall_status":"UNKNOWN","enrollment_count":50000,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT03423641","title":"An Observational Study of the Safety of Direct-acting Antivirals in Patients With Hepatitis C","phase":"","overall_status":"COMPLETED","enrollment_count":33808,"lead_sponsor_name":"Kaiser Permanente","has_results":true},{"nct_id":"NCT04035837","title":"The Clinical Cure Project of Chronic Hepatitis B in China","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":30000,"lead_sponsor_name":"Third Affiliated Hospital, Sun Yat-Sen University","has_results":false},{"nct_id":"NCT06306300","title":"Safety and Efficacy of Decentralized HCV Treatment vs Standard-of-Care in Rio de Janeiro (Brazil)","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":30000,"lead_sponsor_name":"Oswaldo Cruz Foundation","has_results":false},{"nct_id":"NCT06155006","title":"Adult Screening for Hepatitis c and Linkage to Treatment in Hospitals in Colombia","phase":"","overall_status":"RECRUITING","enrollment_count":25669,"lead_sponsor_name":"Asociación Colombiana de Hepatología","has_results":false},{"nct_id":"NCT04943588","title":"Treating Hepatitis C in Pakistan. Strategies to Avoid Resistance to Antiviral Drugs","phase":"","overall_status":"RECRUITING","enrollment_count":25000,"lead_sponsor_name":"Queen Mary University of London","has_results":false},{"nct_id":"NCT03712553","title":"Behavioral Science and Hepatitis C Screening Outreach","phase":"NA","overall_status":"COMPLETED","enrollment_count":21493,"lead_sponsor_name":"University of Pennsylvania","has_results":false},{"nct_id":"NCT05937178","title":"Real-world Study Optimizing Nucleotide-analogues","phase":"","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Huashan Hospital","has_results":false},{"nct_id":"NCT04540081","title":"Enhancing Electronic Health Systems to Decrease the Burden of Colon Cancer, Lung Cancer, Obesity, Vaccine-Preventable Illness, and LivER Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":20000,"lead_sponsor_name":"University of California, Davis","has_results":false},{"nct_id":"NCT06248580","title":"Find HDV and Determine Its Status in Turkey","phase":"","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Yaşar Bayındır, MD","has_results":false},{"nct_id":"NCT05906459","title":"Simplification and Test and Treat Strategies Towards Hepatitis C Eliminationplatform\" in China(STAT)","phase":"","overall_status":"UNKNOWN","enrollment_count":20000,"lead_sponsor_name":"Huashan Hospital","has_results":false},{"nct_id":"NCT02759991","title":"Effectiveness Trial to Evaluate Protection of Pregnant Women by Hepatitis E Vaccine in Bangladesh.","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":19460,"lead_sponsor_name":"Norwegian Institute of Public Health","has_results":false},{"nct_id":"NCT04525833","title":"Liver Disease and Other Systemic Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":15000,"lead_sponsor_name":"Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation","has_results":false},{"nct_id":"NCT06847958","title":"HepC Micro-elimination on MSM and TGW Population.","phase":"","overall_status":"COMPLETED","enrollment_count":13161,"lead_sponsor_name":"Projecte dels NOMS Hispanosida","has_results":false},{"nct_id":"NCT03706742","title":"STOP HCC: Mailed HCV Treatment Outreach Program for HCC Prevention","phase":"NA","overall_status":"COMPLETED","enrollment_count":12386,"lead_sponsor_name":"University of Texas Southwestern Medical Center","has_results":false},{"nct_id":"NCT02749864","title":"Study to Evaluate the Prevalence of Hepatitis C in Spain in 2015 (PREVHEP)","phase":"","overall_status":"COMPLETED","enrollment_count":12246,"lead_sponsor_name":"Instituto de Investigación Marqués de Valdecilla","has_results":false},{"nct_id":"NCT01681420","title":"Improving Blood Safety and HIV Testing in Brazil","phase":"NA","overall_status":"COMPLETED","enrollment_count":11900,"lead_sponsor_name":"Vitalant Research Institute","has_results":false},{"nct_id":"NCT04538651","title":"A Cross-sectional Study for Renal Function of Patients With Chronic Hepatitis B in China","phase":"","overall_status":"UNKNOWN","enrollment_count":11453,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT03794791","title":"A Comprehensive HBsAg-positive Patients Centered Screening Strategy","phase":"","overall_status":"COMPLETED","enrollment_count":10000,"lead_sponsor_name":"Hong Ren","has_results":false},{"nct_id":"NCT04677842","title":"European Pregnancy and Paediatric Infections Cohort Collaboration: Paediatric Protocol","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"PENTA Foundation","has_results":false},{"nct_id":"NCT05057065","title":"A Clinical Research on Disease Progression and Intervention of Chronic HepatitisB","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Hong Ren","has_results":false},{"nct_id":"NCT04724785","title":"Real World Study About Anti-viral Regimen Adjustment on Achieving Complete Response in CHB Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"The Second Affiliated Hospital of Chongqing Medical University","has_results":false},{"nct_id":"NCT04025944","title":"Real World Study of Chronic Viral Hepatitis","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Huashan Hospital","has_results":false},{"nct_id":"NCT02393365","title":"Prevalence and Screening of Hepatitis C in Belgium in 2015","phase":"NA","overall_status":"COMPLETED","enrollment_count":10000,"lead_sponsor_name":"Brugmann University Hospital","has_results":false},{"nct_id":"NCT02657694","title":"Reviewing DAA Efficacy Managing Patient Treatment In Online Neighbourhoods","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"FixHepC","has_results":false},{"nct_id":"NCT06049602","title":"TDF and Entekavir - Hepatitis B Reactivation","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Viral Hepatitis Society","has_results":false},{"nct_id":"NCT00001971","title":"Evaluation of Patients With Liver Disease","phase":"","overall_status":"RECRUITING","enrollment_count":8050,"lead_sponsor_name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","has_results":false},{"nct_id":"NCT03992313","title":"Community Versus Facility-based Services to Improve the Screening of Active HCV Infection in Cambodia","phase":"NA","overall_status":"COMPLETED","enrollment_count":7692,"lead_sponsor_name":"ANRS, Emerging Infectious Diseases","has_results":false},{"nct_id":"NCT04525690","title":"Improving Inpatient Screening for Hepatitis C","phase":"NA","overall_status":"COMPLETED","enrollment_count":7634,"lead_sponsor_name":"University of Pennsylvania","has_results":false},{"nct_id":"NCT01679834","title":"An Observational Study of Pegasys in Dual- or Triple-Therapy in Patients With Chronic Hepatitis C","phase":"","overall_status":"COMPLETED","enrollment_count":7500,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT06539052","title":"MIGrant Reflex Test HDV (MIGRED) Project","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":7500,"lead_sponsor_name":"University of Campania Luigi Vanvitelli","has_results":false},{"nct_id":"NCT07388979","title":"MAGIA H3S Point of Care Test Performance for HIV, HBV, HCV, and Syphilis Screening in Pregnant Women in DR Congo","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":7500,"lead_sponsor_name":"Gardiens de Vies","has_results":false},{"nct_id":"NCT01457755","title":"Gilead Sustained Virologic Response (SVR) Registry","phase":"","overall_status":"COMPLETED","enrollment_count":6625,"lead_sponsor_name":"Gilead Sciences","has_results":false},{"nct_id":"NCT03595527","title":"Universal HIV Screening and Targeted HCV Screening in Emergency Department","phase":"NA","overall_status":"COMPLETED","enrollment_count":6350,"lead_sponsor_name":"Centre hospitalier de l'Université de Montréal (CHUM)","has_results":true},{"nct_id":"NCT07258251","title":"Strengthening Hepatitis B Screening, Linkage to Care and Long-Term Monitoring in Phichit Province, Thailand: A Birth Bohort Approach","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":6000,"lead_sponsor_name":"The Task Force for Global Health","has_results":false},{"nct_id":"NCT03685045","title":"ETHOS ENGAGE: Enhancing Treatment of Hepatitis C in Opioid Substitution Settings","phase":"NA","overall_status":"UNKNOWN","enrollment_count":6000,"lead_sponsor_name":"Kirby Institute","has_results":false},{"nct_id":"NCT03526939","title":"DRug Use and Infections in Hai Phong ViEtnam Among Persons Who Inject Drugs","phase":"","overall_status":"COMPLETED","enrollment_count":5546,"lead_sponsor_name":"New York University","has_results":false},{"nct_id":"NCT06349902","title":"Re-link HCV in Substance-Use Telemedicine Program","phase":"","overall_status":"UNKNOWN","enrollment_count":5000,"lead_sponsor_name":"trueNorth Medical Centres","has_results":false},{"nct_id":"NCT04483518","title":"Epidemiological Survey of Hepatitis D Virus Infection in China","phase":"","overall_status":"COMPLETED","enrollment_count":5000,"lead_sponsor_name":"The First Hospital of Jilin University","has_results":false},{"nct_id":"NCT05182463","title":"Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Third Affiliated Hospital, Sun Yat-Sen University","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}